Citigroup has given a positive outlook on Anthem Biosciences, predicting a price of ₹870 based on anticipated growth in their CRDMO (Contract Development and Manufacturing Organization) segment. The financial firm estimates a robust revenue growth rate of 26% for FY23-26, along with a steady EBITDA growth rate of 22% from FY26-28.

Citi Group now recommends buying shares in Anthem Biosciences, predicting the stock could reach ₹870. Investors might want to consider this bullish forecast for Anthem Bio's future.